Provided by Tiger Trade Technology Pte. Ltd.

Alnylam Pharmaceuticals

224.53
+0.12000.05%
Post-market: 224.530.00000.00%16:42 EDT
Volume:1.76M
Turnover:392.91M
Market Cap:29.96B
PE:39.96
High:225.90
Open:222.03
Low:218.39
Close:224.41
52wk High:495.55
52wk Low:197.81
Shares:133.43M
Float Shares:133.16M
Volume Ratio:1.19
T/O Rate:1.32%
Dividend:- -
Dividend Rate:- -
EPS(TTM):5.62
EPS(LYR):2.33
ROE:96.55%
ROA:12.34%
PB:22.12
PE(LYR):96.36

Loading ...

Movement Alert|Alnylam Pharmaceuticals Rises 6.11% in Pre-Market Trading, Trading at $336.95

Market Focus
·
Jul 09

Movement Alert|Alnylam Pharmaceuticals Rises 5.1% Overnight, Trading at $340.0

Market Focus
·
Jul 09

Astrazeneca's Wainua Fails Key Heart Disease Trial, Shares Tumble

Reuters
·
Jul 09

Kalaris Appoints Laurie Keating to Board, Replacing Morana Jovan-embiricos

Reuters
·
Jul 07

NASDAQ Top and Bottom Performing Stocks at About 11:01 A.m. EDT on 2026-07-02

Reuters
·
Jul 02

Movement Alert|Alnylam Pharmaceuticals Rises 5.01% in Regular Trading, Multiple Partnership Catalysts Fuel Rally Amid Biotech Sector Strength

Market Focus
·
Jul 02

Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (ALNY), Biohaven Ltd. (BHVN) and Praxis Precision Medicines (PRAX)

TIPRANKS
·
Jun 29

Alnylam Pharmaceuticals is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Jun 29

Alnylam Pharmaceuticals, Inc. : H.c. Wainwright Cuts Target Price to $470 from $510

THOMSON REUTERS
·
Jun 29

Alnylam price target lowered to $470 from $510 at H.C. Wainwright

TIPRANKS
·
Jun 29

Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (ALNY) and Cytokinetics (CYTK)

TIPRANKS
·
Jun 29

Alnylam Pharma (ALNY) Receives a Buy from Barclays

TIPRANKS
·
Jun 29

U.S. Research Roundup-3m Co, Nike, Primoris Services

Reuters
·
Jun 29

Alnylam Posts Aln-6400 Plasminogen-targeting Rnai Therapy Presentation on Rare Bleeding Disorders

Reuters
·
Jun 26

Komodo Health Expands Strategic Partnership with Alnylam to Scale Marmot AI Analytics Platform

Reuters
·
Jun 25

Oppenheimer Sticks to Their Buy Rating for Alnylam Pharma (ALNY)

TIPRANKS
·
Jun 25

Movement Alert|Alnylam Pharmaceuticals Rises 5.1% in Regular Trading, Trading at $302.29

Market Focus
·
Jun 25

Regeneron Gets FDA, EMA Review of Cemdisiran in Generalized Myasthenia Gravis

Dow Jones
·
Jun 22

Barclays Reaffirms Their Buy Rating on Alnylam Pharma (ALNY)

TIPRANKS
·
Jun 22

RBC Capital Remains a Buy on Alnylam Pharma (ALNY)

TIPRANKS
·
Jun 22